Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs NetEase Inc (NTES) Price & Performance

Abeona Therapeutics IncTrade
NetEase IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs NetEase Inc — how do they compare? Abeona Therapeutics Inc trades at $7.56 (market cap $424.33M), while NetEase Inc trades at $123.38 (market cap $83.89B). The key difference: NetEase Inc is far larger — about 197.7× Abeona Therapeutics Inc's market cap, and NetEase Inc pays a 2.26% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEONTES
Market Cap
$424.33M$83.89B
Sector
HealthMedia
52-Week High
$7.45$159.34
52-Week Low
$4.17$109.26
Enterprise Value
$279.23M$60.18B
Dividend Yield
2.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.

Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.

NetEase Inc

NTES trades at $132.22, up 1.43% today, with a bullish technical signal from moving averages and support near $131. The company reported Q1 2026 EPS of $2.53, beating estimates, and maintains strong profitability with a 29.84% net income margin. Recent news highlights upcoming Q2 2026 earnings on August 20, 2026, amid positive sentiment for Chinese tech stocks.

Outlook is positive with 82% analyst buy ratings and a 34.7% upside potential, though risks include earnings volatility and regulatory pressures. Revenue growth to $114.4B in 2026 and robust cash flow support valuation, but investors should monitor execution amid competitive and macroeconomic challenges.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About NetEase Inc

NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).

Read more on NTES